N-[顺-4-[[[4-(二甲基氨基)-2-喹唑啉基]氨基]环己基]-3,4-二氟苯甲酰胺盐酸盐 | 510733-97-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: N-[顺-4-[[[4-(二甲基氨基)-2-喹唑啉基]氨基]环己基]-3,4-二氟苯甲酰胺盐酸盐
• 英文名称: Benzamide, N-(cis-4-((4-(dimethylamino)-2-quinazolinyl)amino)cyclohexyl)-3,4-difluoro-, monohydrochloride
• 英文别名: N-[4-[[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-3,4-difluorobenzamide;hydrochloride
• CAS: 510733-97-8
• 化学式: C23H26ClF2N5O
• 分子量: 461.9
• InChiKey: HUUPKFUYSQNNLO-UHFFFAOYSA-N

物化性质

• 溶解度：
  在DMSO中的溶解度为5mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  4.55
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  70.2
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Mch receptor antagonists
  申请人：Sekiguchi Yoshinori

  公开号：US20070037836A1

  公开（公告）日：2007-02-15

  The present invention relates to novel compounds of the formula (I) which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression.

  本发明涉及具有式(I)的新型化合物，其作为MCH受体拮抗剂。这些组合物在药物组合物中有用，其使用包括预防或治疗肥胖症、与肥胖相关的疾病、焦虑或抑郁症。
• MCH RECEPTOR ANTAGONISTS
  申请人：Taisho Pharmaceutical Co. Ltd.

  公开号：EP1432693A2

  公开（公告）日：2004-06-30
• COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY
  申请人：ZOGENIX INTERNATIONAL LIMITED

  公开号：US20170071949A1

  公开（公告）日：2017-03-16

  Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome.
• US7544690B2
  申请人：——

  公开号：US7544690B2

  公开（公告）日：2009-06-09
• [EN] MCH RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR DE LA MCH
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2003028641A2

  公开（公告）日：2003-04-10

  The present invention relates to novel compounds of the formula (I) which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression.